Table 2.
Changes of the Investigated Parameters by Treatment Arm from Baseline to Endpointa
| Pioglitazone + metformin | Glimepiride + metformin | |||
|---|---|---|---|---|
| Baseline | Endpoint | Baseline | Endpoint | |
| Hemoglobin A1c (%) | 7.4 ± 0.8 | 6.6 ± 0.9b | 6.7 ± 0.5 | 6.0 ± 0.5b |
| Biomarker of platelet function | ||||
| Thromboxane B2 (pg/ml) | 1337 ± 1197 | 1121 ± 753 | 756 ± 433 | 1284 ± 1046 |
| Glycoprotein II/III complex inhibition (PAU) | 134 ± 67 | 143 ± 63 | 153 ± 41 | 144 ± 35 |
| vWillebrand factor (%) | 148 ± 62 | 128 ± 53b | 129 ± 50 | 130 ± 31 |
| Biomarker of chronic systemic inflammation | ||||
| hsCRP (≤10 mg/liter) (mg/liter) | 2.32 ± 1.88 | 1.26 ± 1.12b | 2.64 ± 2.58 | 2.71 ± 2.79c |
| sCD40L (pg/ml) | 388 ± 379 | 348 ± 518 | 285 ± 158 | 387 ± 372 |
| Matrix metallopeptidase 9 (ng/ml) | 429 ± 197 | 461 ± 280 | 460 ± 203 | 511 ± 276 |
| Soluble intracellular adhesion molecule (ng/ml) | 274 ± 73 | 261 ± 78 | 276 ± 69 | 273 ± 84 |
| Soluble vascular cell adhesion molecule (ng/ml) | 752 ± 267 | 763 ± 269 | 630 ± 117 | 633 ± 190 |
| E-selectin (ng/ml) | 22 ± 9 | 18 ± 7b | 20 ± 5 | 19 ± 4 |
| Lipids | ||||
| Total cholesterol (mg/dl) | 191 ± 33 | 194 ± 41 | 159 ± 48 | 163 ± 52 |
| HDL cholesterol (mg/dl) | 43 ± 7 | 45 ± 10 | 41 ± 7 | 40 ± 8 |
| Low-density lipoprotein cholesterol (mg/dl) | 105 ± 33 | 114 ± 34b | 85 ± 30 | 100 ± 36b |
| Triglycerides (mg/dl) | 263 ± 119 | 160 ± 52b | 155 ± 52 | 149 ± 65c |
a
Data are given as mean values ± standard deviation.
b
p < .05 versus baseline.
c
p < .05 for changes between the groups from baseline.